Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBT: 2017-2025

Historic EBT for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to -$39.3 million.

  • Protagonist Therapeutics' EBT fell 16.98% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year decrease of 72.23%. This contributed to the annual value of $279.4 million for FY2024, which is 453.88% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported EBT of -$39.3 million as of Q3 2025, which was down 13.70% from -$34.6 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' EBT registered a high of $210.7 million during Q1 2024, and its lowest value of -$41.0 million during Q2 2022.
  • Moreover, its 3-year median value for EBT was -$33.6 million (2024), whereas its average is $10.4 million.
  • As far as peak fluctuations go, Protagonist Therapeutics' EBT plummeted by 335.45% in 2021, and later surged by 724.66% in 2024.
  • Quarterly analysis of 5 years shows Protagonist Therapeutics' EBT stood at -$37.2 million in 2021, then rose by 7.77% to -$34.3 million in 2022, then soared by 179.78% to $27.3 million in 2023, then surged by 388.98% to $133.7 million in 2024, then decreased by 16.98% to -$39.3 million in 2025.
  • Its last three reported values are -$39.3 million in Q3 2025, -$34.6 million for Q2 2025, and -$11.7 million during Q1 2025.